1. Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.
- Author
-
Cheng AL, Li J, Vaid AK, Ma BB, Teh C, Ahn JB, Bello M, Charoentum C, Chen LT, de Lima Lopes G Jr, Ho GF, Kong HL, Lam KO, Liu TS, Park YS, Sriuranpong V, Sudoyo AW, Wang JY, Zhang J, Zhang SZ, Ciardiello F, Köhne CH, Shaw M, and Kim TW more...
- Subjects
- Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Asia, Bevacizumab, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Capecitabine, Cetuximab, Colonic Neoplasms genetics, Colonic Neoplasms pathology, Combined Modality Therapy, Deoxycytidine analogs & derivatives, Deoxycytidine therapeutic use, Drug Combinations, ErbB Receptors antagonists & inhibitors, Fluorouracil administration & dosage, Fluorouracil analogs & derivatives, Fluorouracil therapeutic use, Guideline Adherence, Humans, Leucovorin administration & dosage, Liver Neoplasms genetics, Liver Neoplasms secondary, Lung Neoplasms genetics, Lung Neoplasms secondary, Magnetic Resonance Imaging, Metastasectomy, Neoplasm Staging, Organoplatinum Compounds administration & dosage, Oxaloacetates, Oxonic Acid administration & dosage, Panitumumab, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins p21(ras), Rectal Neoplasms genetics, Rectal Neoplasms pathology, Tegafur administration & dosage, Tomography, X-Ray Computed, ras Proteins genetics, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colonic Neoplasms therapy, Liver Neoplasms therapy, Lung Neoplasms therapy, Practice Guidelines as Topic, Rectal Neoplasms therapy
- Abstract
Colorectal cancer (CRC) is among the most common cancers worldwide, but marked epidemiological differences exist between Asian and non-Asian populations. Hence, a consensus meeting was held in Hong Kong in December 2012 to develop Asia-specific guidelines for the management of metastatic CRC (mCRC). A multidisciplinary expert panel, consisting of 23 participants from 10 Asian and 2 European countries, discussed current guidelines for colon or rectal cancer and developed recommendations for adapting these guidelines to Asian clinical practice. Participants agreed that mCRC management in Asia largely follows international guidelines, but they proposed a number of recommendations based on regional 'real-world' experience. In general, participants agreed that 5-fluorouracil (5-FU) infusion regimens in doublets can be substituted with UFT (capecitabine, tegafur-uracil) and S1 (tegafur, 5-chloro-2,4-dihydroxypyridine and oxonic acid), and that the monoclonal antibodies cetuximab and panitumumab are recommended for KRAS wild type tumors. For KRAS mutant tumors, bevacizumab is the preferred biological therapy. FOLFOX (folinic acid, 5-FU, and oxaliplatin) is preferred for initial therapy in Asian patients. The management of mCRC is evolving, and it must be emphasized that the recommendations presented here reflect current treatment practices and thus might change as more data become available., (Copyright © 2014 Elsevier Inc. All rights reserved.) more...
- Published
- 2014
- Full Text
- View/download PDF